Cargando…
Isoflavone diet ameliorates experimental autoimmune encephalomyelitis through modulation of gut bacteria depleted in patients with multiple sclerosis
The gut microbiota is a potential environmental factor that influences the development of multiple sclerosis (MS). We and others have demonstrated that patients with MS and healthy individuals have distinct gut microbiomes. However, the pathogenic relevance of these differences remains unclear. Prev...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270496/ https://www.ncbi.nlm.nih.gov/pubmed/34244137 http://dx.doi.org/10.1126/sciadv.abd4595 |
_version_ | 1783720815539257344 |
---|---|
author | Jensen, Samantha N. Cady, Nicole M. Shahi, Shailesh K. Peterson, Stephanie R. Gupta, Arnav Gibson-Corley, Katherine N. Mangalam, Ashutosh K. |
author_facet | Jensen, Samantha N. Cady, Nicole M. Shahi, Shailesh K. Peterson, Stephanie R. Gupta, Arnav Gibson-Corley, Katherine N. Mangalam, Ashutosh K. |
author_sort | Jensen, Samantha N. |
collection | PubMed |
description | The gut microbiota is a potential environmental factor that influences the development of multiple sclerosis (MS). We and others have demonstrated that patients with MS and healthy individuals have distinct gut microbiomes. However, the pathogenic relevance of these differences remains unclear. Previously, we showed that bacteria that metabolize isoflavones are less abundant in patients with MS, suggesting that isoflavone-metabolizing bacteria might provide protection against MS. Here, using a mouse model of MS, we report that an isoflavone diet provides protection against disease, which is dependent on the presence of isoflavone-metabolizing bacteria and their metabolite equol. Notably, the composition of the gut microbiome in mice fed an isoflavone diet exhibited parallels to healthy human donors, whereas the composition in those fed an isoflavone-free diet exhibited parallels to patients with MS. Collectively, our study provides evidence that dietary-induced gut microbial changes alleviate disease severity and may contribute to MS pathogenesis. |
format | Online Article Text |
id | pubmed-8270496 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Association for the Advancement of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-82704962021-07-16 Isoflavone diet ameliorates experimental autoimmune encephalomyelitis through modulation of gut bacteria depleted in patients with multiple sclerosis Jensen, Samantha N. Cady, Nicole M. Shahi, Shailesh K. Peterson, Stephanie R. Gupta, Arnav Gibson-Corley, Katherine N. Mangalam, Ashutosh K. Sci Adv Research Articles The gut microbiota is a potential environmental factor that influences the development of multiple sclerosis (MS). We and others have demonstrated that patients with MS and healthy individuals have distinct gut microbiomes. However, the pathogenic relevance of these differences remains unclear. Previously, we showed that bacteria that metabolize isoflavones are less abundant in patients with MS, suggesting that isoflavone-metabolizing bacteria might provide protection against MS. Here, using a mouse model of MS, we report that an isoflavone diet provides protection against disease, which is dependent on the presence of isoflavone-metabolizing bacteria and their metabolite equol. Notably, the composition of the gut microbiome in mice fed an isoflavone diet exhibited parallels to healthy human donors, whereas the composition in those fed an isoflavone-free diet exhibited parallels to patients with MS. Collectively, our study provides evidence that dietary-induced gut microbial changes alleviate disease severity and may contribute to MS pathogenesis. American Association for the Advancement of Science 2021-07-09 /pmc/articles/PMC8270496/ /pubmed/34244137 http://dx.doi.org/10.1126/sciadv.abd4595 Text en Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC). https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license (https://creativecommons.org/licenses/by-nc/4.0/) , which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited. |
spellingShingle | Research Articles Jensen, Samantha N. Cady, Nicole M. Shahi, Shailesh K. Peterson, Stephanie R. Gupta, Arnav Gibson-Corley, Katherine N. Mangalam, Ashutosh K. Isoflavone diet ameliorates experimental autoimmune encephalomyelitis through modulation of gut bacteria depleted in patients with multiple sclerosis |
title | Isoflavone diet ameliorates experimental autoimmune encephalomyelitis through modulation of gut bacteria depleted in patients with multiple sclerosis |
title_full | Isoflavone diet ameliorates experimental autoimmune encephalomyelitis through modulation of gut bacteria depleted in patients with multiple sclerosis |
title_fullStr | Isoflavone diet ameliorates experimental autoimmune encephalomyelitis through modulation of gut bacteria depleted in patients with multiple sclerosis |
title_full_unstemmed | Isoflavone diet ameliorates experimental autoimmune encephalomyelitis through modulation of gut bacteria depleted in patients with multiple sclerosis |
title_short | Isoflavone diet ameliorates experimental autoimmune encephalomyelitis through modulation of gut bacteria depleted in patients with multiple sclerosis |
title_sort | isoflavone diet ameliorates experimental autoimmune encephalomyelitis through modulation of gut bacteria depleted in patients with multiple sclerosis |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270496/ https://www.ncbi.nlm.nih.gov/pubmed/34244137 http://dx.doi.org/10.1126/sciadv.abd4595 |
work_keys_str_mv | AT jensensamanthan isoflavonedietamelioratesexperimentalautoimmuneencephalomyelitisthroughmodulationofgutbacteriadepletedinpatientswithmultiplesclerosis AT cadynicolem isoflavonedietamelioratesexperimentalautoimmuneencephalomyelitisthroughmodulationofgutbacteriadepletedinpatientswithmultiplesclerosis AT shahishaileshk isoflavonedietamelioratesexperimentalautoimmuneencephalomyelitisthroughmodulationofgutbacteriadepletedinpatientswithmultiplesclerosis AT petersonstephanier isoflavonedietamelioratesexperimentalautoimmuneencephalomyelitisthroughmodulationofgutbacteriadepletedinpatientswithmultiplesclerosis AT guptaarnav isoflavonedietamelioratesexperimentalautoimmuneencephalomyelitisthroughmodulationofgutbacteriadepletedinpatientswithmultiplesclerosis AT gibsoncorleykatherinen isoflavonedietamelioratesexperimentalautoimmuneencephalomyelitisthroughmodulationofgutbacteriadepletedinpatientswithmultiplesclerosis AT mangalamashutoshk isoflavonedietamelioratesexperimentalautoimmuneencephalomyelitisthroughmodulationofgutbacteriadepletedinpatientswithmultiplesclerosis |